A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.

PHASE1CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

October 29, 2024

Study Completion Date

October 29, 2024

Conditions
Inflammatory Diseases
Interventions
DRUG

AZD6793

AZD6793 will be administered orally

DRUG

Placebo

Placebo will be administered orally

Trial Locations (2)

HA1 3UJ

Research Site, Harrow

M23 9QZ

Research Site, Wythenshawe

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY